Trials / Unknown
UnknownNCT02683655
Study of Apatinib in Metastatic Esophageal Cancer
Study of Apatinib in Metastatic Esophageal Cancer：A Open Label, Randomized Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Huai'an First People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic Esophageal Cancer.
Detailed description
Eligible patients will receive apatinib treatment until disease progression or intolerable toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib 500mg qd p.o. |
| DRUG | Apatinib | Apatinib 750mg qd p.o. |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-10-01
- First posted
- 2016-02-17
- Last updated
- 2016-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02683655. Inclusion in this directory is not an endorsement.